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Abstract
Nowadays, type I diabetes mellitus is a pathology afflicting millions of people globally 
with a dramatic assessment in the next future. Current treatments including exogenous 
insulin, pancreas transplantation and islets transplantation, are not free from important 
lifelong side effects. In the last decade, tissue engineering and regenerative medicine have 
shown encouraging results about the possibility to produce a functional bioengineered 
pancreas. Among many technologies, decellularization offers the opportunity to produce 
an organ-specific acellular matrix that could subsequently repopulate with endocrine cel-
lular population. Herein, we aim to review the state-of-art and this technology highlight-
ing the diabetes burden for the healthcare system and the major achievements toward 
the manufacturing of a bioengineered pancreas obtained by cell-on-scaffold technology.
Keywords: regenerative medicine, pancreas, extracellular matrix, scaffold, 
bioengineered pancreas
1. Introduction: definition of diabetes and diabetes’ impact on the 
economy and future projections
In 2014, the World Health Organization (WHO) has estimated diabetes as a worldwide dis-
ease afflicting 422 million people with an increasing, globally, heavy burden both for the 
health-care system and the economic policies [1]. As stated in 2014 by National Diabetes 
Statistics Report [2] T1D, the so-called diabetes mellitus, is a chronic metabolic disorder, 
which is afflicting around 9.3% of worldwide adult population widely counting 29.1 million 
people worldwide. Moreover this data could even be worse if considering prediabetes or 
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borderline diabetes global prevalence of around 7.8% (343 M) [3]. In this regards, according 
to ADA expert panel, in 20 years, without any kind of therapeutic intervention, it is reason-
able to estimate that up to 70% of prediabetic individuals will develop a “real” diabetic status 
[4], whereas, individuals with lifestyle modifications and drug intervention, normoglycemic 
conversion will take place ranging from 35 to 50% of cases [5] in a 10-years follow-up cohort. 
Starting from these data, the prospective future scenario is dramatic.
In the 7th Edition of the Diabetes Atlas, the International Diabetes Federation (IDF) has 
recently estimated that by 2040, 1 out 10 adult individuals will suffer of diabetes (actually the 
estimation is set to 1 out 11 adults) with a global picture of more than 640 M of people (raised 
from actual 415 M) [5]. This scenario will also have huge impact on economic health-care poli-
cies. Nowadays, the direct cost of diabetes hits 825 billion dollars a year [6] to whom should 
be added all the indirect costs deriving from diabetes consequences.
Diabetes is currently recognized as a group of different metabolic disorders, which led to the 
same final outcome: the organism incapacity to manage intracorporeal glucose levels.
This inability can be referred to two main physiological alterations and consequently to two 
principal diabetes categories: type 1 and type 2 diabetes.
Type 1 diabetes (T1D) (also recognized as autoimmune or juvenile diabetes) is a lifelong 
chronic autoimmune disease characterized by insulin deficiency due to pancreatic β cells loss 
and, therefore to a subsequent hyperglycemia status [7].
Type 2 diabetes (T2D) (formerly called non-insulin-dependent or adult-onset) represents the 
most common type of diabetes grossly counting 90% of all cases worldwide. T2D pathophysi-
ology is related to genetic and epigenetic factors, environmental conditions and lifestyle (obe-
sity, physical activity and diet) that bring to a mixture of hyper-insulinemia, insulin resistance 
and pancreatic β cells failure [8, 9].
If insulin resistance cannot be treated by bioengineering approach, insulin deficiency, typical 
of T1D, could surely benefit bioengineered pancreas.
T1D is a chronic autoimmune metabolic disease characterized by hyperglycemia, which is 
secondary to insulin deficiency that develops as consequence of the numerical loss of the 
pancreatic islet β cells. This loss is due in 70–90% of cases by an autoimmunity disorder 
that brings to a cascade characterized by β cells destruction, dysglycemia and finally hyper-
glycemia. It represents 5–10% of whole diabetes cases with more than 20 million people 
worldwide [10]. This disease is also marked by numerous short- or long-term complica-
tions. Acute complications include life-threatening crisis ranging from severe hypoglycemic 
episodes to diabetic ketoacidosis. Long-term complications comprise chronic micro- and 
macro-vascular diseases including retinopathy, nephropathy and neuropathy due to stroke 
and ischemic heart attack. This panorama leads, in almost all cases, to lifelong disabilities 
reducing, at the same time, quality and expectancy of life and involving immense health-
care expenditures.
As deeply analyzed by Dall et al. in 2007, at that time, the estimated cost for T1D patient for 
year was around 3000 pounds (versus around 2000 pounds estimated for T2D patient for 
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year), which includes direct medical costs and indirect costs (such as productivity loss or pre-
mature mortality) [11]. These data dramatically changed in recent years accompanying to a 
huge increase both to the worldwide number of diabetic patients as well as the deriving costs. 
The World Health Organization [12] has estimated for the 2014 a total of 422 million diabetic 
people which, compared to 108 millions counted in 1980, have more than triplicated the total 
global health-care spending for diabetes reaching 827 USD billion/year. [13, 14]. Forecasting 
models and projections define a situation where diabetes will be pandemic. Recently Krohe 
et al. has published their future projection for 2030 indicating an increase of the American 
prevalence (type 1 and type 2 diabetes) of around 54% with a 54.9 M people afflicted by the 
disease and a total cost increase of 53%, 622 billion USD just for the US population [15].
2. Historical development and current therapeutic options for diabetes’ 
treatment
2.1. Insulin approach
Diabetes was born in 1910 when the English physiologist Sir Edward Albert Sharpey-Schafer 
discovers a substance normally produced by non-diabetic patients: insulin. The name derives 
from the Latin word “insula” means island, referring to the islets of Langerhans (www.dia-
betes.org), is a specific structure that is able to produce insulin in the pancreas. Since then, 
all the efforts have focused on the possibility to isolate this substance in order to replace for 
diabetic patients (so far described as simple, non-producing insulin patients) [16]. This need 
was driven by the fact that, without a substitute, diabetes was a pathologic condition that 
would surely have led to death. In 1921, Banting and Macleod (Nobel prize in Physiology 
or Medicine in 1923) succeeded in isolating insulin from a canine diabetic model, literally 
revolutionizing the entire health world. One year later, with this pioneering finding, the first 
diabetic patient was treated. Since then, several modifications have been completed, making 
the insulin replacement more refined, from slower acting insulin (the first form was intro-
duced in 1936) to genetically engineered artificial “human” insulin that was produced in 1978 
exploiting Escherichia coli bacteria able to avoid frequent allergic reactions derived from the 
use of cattle or porcine insulin. Nowadays, exogenous insulin administration is considered as 
an essential therapy for patients affected by T1D, being able to avoid, when accurately man-
aged, acute metabolic compensations.
It is said that insulin is not a “perfect therapy” as it is being accompanied by several side 
effects, both in short- and long period and finally considering that just 40% of treated patients 
achieve and maintain a satisfying glucose range [17]. In fact, there are different factors influ-
encing the effectiveness of insulin therapy such as daily stress, the food intake and the physi-
cal activity [18] highlighting the vital importance of a baseline good lifestyle management 
[19]. Insulin therapy for T1D is based on multiple daily subcutaneous injections of insulin try-
ing to follow a patient-tailored scheme created by considering patient carbohydrate assump-
tion, pre-meal glucose levels and anticipated physical activity [20]. Recently, a continuous 
intra-venous insulin administration has been considered as a simpler way for exogenous 
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insulin administration in order to match insulin requirements. This approach can be effectively 
considered useful for perioperative period of patients who has undergone surgery [21, 22] 
but it could not be used as a lifelong option due to the modest differences between the two 
delivering systems [23] in terms of final outcomes.
Even with some limitations, insulin treatment represents, as of now, the most widespread 
therapy to face T1D diabetes.
2.2. Pancreas transplantation
Pancreas transplantation has been successfully established for the first time in 1966 by the 
surgical team driven by Prof. W. Kelly [24]. That ground-breaking success has opened a new 
chapter in the transplantation field bringing almost 50,000 transplants performed worldwide 
by 1996 [25, 26]. The worldwide diffusion of this procedure has been strengthened by the 
improvement of surgical technic but, overall, by the discovery around 1980, of immunosup-
pressive drugs that prevent the otherwise unavoidable immunological rejection. Cyclosporine 
was the first immunosuppressive drug tested, which led to very significant improvements 
for long-term patient survival (91% at 1 year and 84% at 3 years, respectively) [25]. Later 
tacrolimus and mycophenolate mofetil have been developed [27] and then also T cell deplet-
ing agents (Alemtuzumab, OKT3 or Minnesota ALG), until the modern immunosuppressive 
regimes, have permitted to abandon the initial immunosuppressive drugs (tacrolimus and 
prednisone) and their side effects (hypertension, hyperlipidemia and nephrotoxicity).
When available, nowadays, pancreas transplantation represents the best treatment to offer 
T1D patient, yielding higher rates of insulin independence compared to insulin treatment or 
islet encapsulation (which will be discussed below) [28]. Additionally, the quality of life and 
the complications, deriving from diabetic status, have more benefits from pancreas transplan-
tation than from insulin therapeutic plan or from islets encapsulation [29, 30].
For the above-explained reasons, pancreas transplantation is known as the only definitive 
long-term treatment for insulin-dependent patients with survival rates of >95% and graft sur-
vival rate at almost 85% at 1 year [31]. The major problem that strongly limits a wider diffusion 
of pancreas transplantation currently is the lack of viable transplantable pancreas. Recently, 
the total of pancreas transplants has been reduced. Between 2005 and 2014, the number of 
pancreas transplants declined by more than 30% as well as the number of candidates on the 
waiting list (−48.0%) [32] with a total of just 954 pancreas transplants performed in the USA 
[33]. This is secondary to several factors including above all shortage of a primary referral 
source, difficulties of acceptance by the diabetes scientific society and developments in diabe-
tes management. The final consequence concerning the effective clinical application is that, in 
the USA, just 3 out 10.000 T1D patients are treated with pancreas or islets transplantation [17].
2.3. Islets transplantation
Islets cell transplantation is one of the most powerful weapons to treat selected T1D patients. 
It is based on the transplantation of a single selected cluster of cells (islets cells) that mainly 
contain β cells responsible for the physiological production of insulin. This procedure is 
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offered only to selected diabetic recipient who did not benefit “standard” insulin treatment 
with severe hypoglycemic episodes (brittle diabetes) and unstable glycemic profile proposing 
the whole pancreas transplantation only in case of very poor metabolic control [34, 35]. Islet 
transplantation has been a solid road to follow just from 1972 via islet isograft performed by 
Lacy and Ballinger who transplanted pancreatic islet in streptozocin-induced diabetic rats 
[36]. These revolutionary data have shown how a cell therapy could be effective in the treat-
ment of diabetes even if the translation to the large animal and, finally, to the clinic was still 
far and full of hurdle to overcome. During the evolution of the whole purification process, 
Ricordi has furnished a significant improvement [37]. He built an automated chamber to opti-
mize and standardize the isolation procedure thus becoming an indispensable tool both for 
animal and human models [38] until becoming an internationally accepted procedure for 
selected candidates. As is done in whole organ pancreas transplantation, the immunosup-
pressive drugs evolution has been crucial also for the development of islet transplantation. 
Till date, immunosuppressive regimes are mandatory after islet transplantation due to the 
source of islets, which need one or more multiple deceased donors in order to be numerically 
sufficient (it has been calculated that 265,000 islets can be grossly sufficient to achieve and 
maintain an insulin-independence status [39] up to 7½ years after transplantation). Later, 
the desired number of transplantable islets cells has been refined and tailored on recipient 
features, up to 5000–10,000 islets equivalents (IEQ) per kg/body mass that is actually recom-
mended as the minimal β cells mass [40] to transplant. The necessity to obtain this number 
of viable islets to transplant faces the organ shortage for whole pancreas transplantation. The 
clinical islet use follows rigid pre-transplant preparation rules, which depend on multi-step 
approach with the final goal to extract, from the whole pancreas, only the islet fraction (that 
represents just 1–2% of the total cellular volume).
The entire process is based on enzymatic digestion, controlled mechanical shear and final 
purification until to enrich a satisfying amount of pure pancreatic islets ready to be injected 
into the recipient [41]. Even if much less invasive compared to pancreas transplantation 
(mainly because of its intravascular portal approach), islets transplantation is not free from 
limitations [42]. Some acute effects comprehend bleeding [43], portal vein thrombosis [44] or 
a transient increase of hepatic inflammatory markers [45]. All these issues most of the times 
are transient and much more important long-term side effects related to immunosuppressive 
regimes (sharing in this way the immunological problems of pancreas transplant).
3. Biomaterials
Biomaterials science is an interdisciplinary field focused on the physical and biological activ-
ity of materials and, furthermore, on their interactions if used in a biological environment.
Conventionally, the most intense development and investigation have been oriented toward 
biomaterials synthesis, optimization, characterization, testing and the biology of host-mate-
rial relations [46]. The global health care has enormously benefited this field through the cre-
ation of heart valve prostheses, artificial hip joints, dental implants, intraocular lenses and 
many other dispositive, becoming the fundamental cornerstones of many modern therapies.
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As reported by the first Consensus of the European Society for Biomaterials in 1976, a bio-
material can be defined as “a nonviable material used in a medical device, intended to inter-
act with biological system” but, alongside the evolution of the field, this definition has been 
evolved into “a material intended to interface with biological system to evaluate, treat, aug-
ment or replace any tissue, organ or function of the body” [46].
Typically we can recapitulate three important big types of biomaterials:
• Ceramics
• Synthetic polymers
• Natural polymers
The correct choice depends on which physiologic function is aimed to augment/replace. For 
example, in case of bone part replacement, a ceramic scaffold (with major strength and higher 
mechanical stiffness) will be preferred, otherwise, for cellular therapies, synthetic/polymers 
will be chosen, favored by their major sustainability in cell behavior.
Scaffolds can be considered as the missing link between biomaterial science and the tissue 
engineering approach and are defined as biomaterial-based tridimensional structures that 
should be able to support cellular viability.
According to the biomaterial from which they are manufactured, scaffolds can be divided as
• Ceramics scaffolds
• Synthetic scaffolds
• Natural scaffolds
Regardless of the material, a scaffold must have precise characteristics and important require-
ments. Biocompatibility is the first mandatory characteristic for every scaffold intended to 
be used in a biological environment. Generally defined as the capacity of a material to be in 
contact with a living tissue or integrated in a living environment by not being toxic, injuri-
ous or physiologically reactive and not causing immunological rejection, biocompatibility’s 
definition has been modified into “the ability of materials to locally trigger and guide wound 
healing, reconstruction and tissue integration” [47].
This new definition moves the focus from an outlook where biomaterials must be simply 
inherent and not causing damages, to a new perspective where they have an active role being 
a dynamic element. Practically, this is exploited by the capacity of biomaterials to receive cells, 
allow their attachment and guarantee their proliferation and differentiation at the same time.
Obviously, after implantation the scaffold must be well integrated and not being the target 
for immunologic reaction.
Mechanical properties are a second important aspect to analyze.
The “ideal” scaffold must present specific mechanical properties suitable both for the ana-
tomical site of implantation (they have also kept mechanical characteristics that make the 
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scaffold handle for surgical implantation) and for the type of cells intended to use. In particu-
lar, using natural scaffolds, mechanotransduction regards the transformation of cellular stress 
into electrochemical responses, crucial for the survival and the right function of both cells and 
higher organisms [48]. Additionally, it has been shown how mechanosensitivity could as well 
facilitate mesenchymal stem cells differentiation [49]. Finally, biological features and biologi-
cal activity include all the cues that the scaffold could reciprocally interchange with seeded 
cells and the biological environment. These kinds of properties, moreover in terms of growth 
factors, chemokines and cytokines, are typical of natural scaffolds suitable to regulate cellular 
functions.
According to these properties four major categorizes of scaffolds are known:
1. Pre-made scaffold for cell seeding [50].
2. Cell sheets with new-secreted extracellular matrix.
3. Cell encapsulation and hydrogel scaffold.
4. Organ extracellular matrix-derived scaffold.
3.1. Pre-made scaffold for cell seeding.
As deeply reviewed by Chan et al., pre-made scaffolds represent the first structure that have 
been seeded with the birth of “tissue engineering” [51]. The idea is to produce a tridimen-
sional structure that are able to furnish a non-toxic environment for seeded cells providing 
a gentle transition by which the scaffold degrades together with the functional enhancement 
and engraftment of seeded cells. Initial pre-made scaffolds were made in the attempt to over-
come limitations due to the “classic” 2D cell culturing, offering all the advantages deriving 
from the third dimension adding a more physiological environment and more predictive data.
The porosity of the scaffold is always been considered as a crucial property for cellular vitality 
for the possibility to guarantee the effective delivering of oxygen and nutrients to cells.
Porosity of the scaffold is also today seen as paradigmatic for an ideal-scaffold. In the review 
of “Porous scaffold design for tissue engineering” [52], the author paraphrased the state of an 
important architect, Robert leRicolais “The art of structure is where to put the holes” trans-
forming it into “The art of scaffolding is where to put the holes and the biofactors”.
This approach has numerous advantages: the choice of biomaterials to use is wide (both 
considering natural or synthetic polymers) and it can exploit a relative precise and repeti-
tive assembling to micrometer size and the material used can be loaded or cross-linked with 
numerous molecules in the attempt to augment cellular functionality [53, 54].
3.2. Cellular sheets approach for tissue engineering
Cell sheets approach, even if considered as scaffold-free technology, must be included in the 
tissue-engineered approach.
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Cell sheets technology has been recently developed by tissue engineering and regenerative 
medicine community has a potential technology able to manufacture layer-by-layer trans-
plantable cellular constructs [55, 56]. The entire principle is based on a particular tempera-
ture-reversible polymer, the poly(N-isopropylacrylamide) (PIPAAm) able to change from an 
hydrophilic to an hydrophobic state at 37 and 32°C, respectively [57].
Cell sheet approach has been tested as a potential approach for pancreatic islets and β cell 
transplantation exploring alternative site of transplantation as well as the intraportal injec-
tion. Subcutaneous site is one of the new sites of islets injection under evaluation (in animal 
model) [58] and the most important difference is the absence of the vascular connection 
between transplanted cells and the blood flow. Moreover, in this regard, other advantages 
can be numbered including less-invasiveness (the hypothetical subcutaneous implanta-
tion could be performed under local anesthesia), the possibility of repeated-procedures in 
case of immunological rejection and, finally, the opportunity to safely remove transplanted 
islets.
In 2009, the group driven by Okano has manufactured a transplantable cell-sheet made by 
rat islets [59]. In their research, rat β cells have been cultured on temperature-responsive 
dishes (with or without adding extracellular matrix) to form a transplantable β cells layer. The 
resulting cellular structure was subcutaneously implanted in streptozotocin-induced diabetic 
immunodeficient mice achieving a euglicemia state after 1 week, which last over 100 days. 
Subcutaneous space is still under analysis in order to be translated to clinics principally due 
a reduced quantity of oxygen and nutrients that can reduce cell viability at long-term [60]. 
Recently Pepper et al. gave place to a newly born use of the subcutaneous site for islet implan-
tation. In order to overcome the limitation of the avascular condition of the subcutaneous 
site, the authors have previously vascularized the implantation site to later infuse in a well-
oxygenated site the islet mass. The final described result showed the possibility to revert the 
hyperglycemic state of severely diabetic induced mice. This innovative approach is recently 
proposed as alternative vascularized site of implantation that can be combined with device or 
scaffolds for beta cell replacement in type 1 diabetes.
3.3. Cell encapsulation and hydrogel scaffold
As previously described, islets transplantation procured from deceased donors is one of the 
most used technology in order reverse a T1D state. Although this procedure is able to pro-
duce a euglicemia state, is not free from side effects and limited principally by donor short-
age, lifelong immunosuppression and the immunological rejection of transplanted islets. The 
use of encapsulation device, able to separate the transplanted β cells from the surrounding 
recipients’ environment, has emerged as a promising approach with the attempt to elimi-
nate the immunological issue and, consequently, the need of immunosuppression [61]. The 
first attempt for encapsulation of human insulinoma tissue dated 1933 by Bisceglie et al. who 
encapsulated human tissue into membranous bags and transplanted into rats [62]. From that 
moment, several encapsulation technologies have been developed and implemented and 
actually they can be sorted into micro- and macroencapsulation technologies depending on 
the size [63] with the recent addition of the nano-encapsulation technology.
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Regardless of the capsule size, the whole approach has a common rationale: enveloping pan-
creatic islets in biocompatible membrane able to permit the diffusion inside the capsule of 
molecules including oxygen and nutrition and, at least in theory, to shield it from larger mol-
ecules such as antibodies or immune cells [64].
In this way, if successful, an immunological physical barrier, through a perm-selective coat-
ing, could prevent the systemic administration of immunosuppressive drugs, which are actu-
ally essential to avoid graft rejection.
Materials for islets encapsulation are deeply studied always searching for better perfor-
mances. It is recognized that two important properties must be developed: firstly, capsule 
must permit the admission inside the capsule (and so on in contact with encapsulated islets) 
of small molecules and the diffusion out of waste material and insulin; secondly, they must 
isolate the content from immune competent cells (B or T cells or macrophages).
These abilities are secondary to the material/s used to produce the capsule.
Alginate, a colloidal substance derived from brown seaweed, is the most famous and the first 
biomaterial suitable to produce capsules. The main advantage of using alginate relies on its 
capacity of not interfering with islets (and with insulin release) while guaranteeing a good 
stability [65]. Several materials are then be added as multiple layers in order to improve algi-
nate functionality. On this subject, poly(ethylene glycol) (PEG) and poly-l-lysine (PLL) are 
the more established aiming to reduce plasma absorption and increasing long-term capsule 
stability. In 1999 Chandy et al. reported a modified encapsulation technique with alginate and 
PEG and showing an improved stability [66]. One year later, Desai et al. showed islets good 
viability and insulin release with the same encapsulation protocol [67]. Alginate/PLL is the 
most utilized combination for cell encapsulation in a multi-layer composition. A three layer 
encapsulation protocol was proposed by Goosen et al., which was based on a alginate/PLL/
alginate composition providing a good shield from immune system and a limited diffusion of 
serum immunoglobulin albumin and hemoglobin [68].
3.3.1. Microencapsulation
In matter of dimension, the size belonging to the microencapsulation group has been the first 
to be developed and examined. In 1984, O’Shea et al. manufactured an alginate-based micro-
capsule [69] open up a new era in islets encapsulation that, after almost 40 years counts more 
than 100 studies in preclinical model (approximately 96% involving small animals). In all 
these settings several strategies have been tested including capsule customization with three 
particular molecules such as the alginate, the glucoronic and mannuronic acids, which if used 
(or combined with other mono/polymer(s)) [70] can confer more strength and stability. Rodent 
preclinical models are the most studied, as reviewed by Souza et al. who have evaluated more 
than 60 encapsulation strategies and have founded that the most effective approach is based 
on the use of intraperitoneal alginate-base microencapsulation without immunosuppressive 
strategies (islets mean survival rate 100 days) and intraportal injection with immunosuppres-
sion (islets mean survival rate 164 days) [71]. Indeed, high mannuronic acid, as biomaterial for 
islets encapsulation, has shown prolonged survival rate for more than 350 days [72].
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3.3.2. Macroencapsulation
Macroencapsulation (or transplantation systems) principle depends on macro-extravascular 
chambers containing the transplanted tissue. This approach has been developed by Algire et al. 
and exploits the presence of a semi-permeable membrane to block immune cells but preserving 
the diffusion of oxygen, nutrients, glucose, insulin, glucagon and somatostatin [73]. Algire’s 
study has paved the way for the creation of a commercially available device that can be trans-
planted [74]. The peculiarity of this chamber resides in the porosity dimension, 450 nm, able to 
avoid the direct contact between islets and immunocompetent cells. Follow-up of this device 
reported a euglicemia state up to 8 months in rodents [75]. Macroencapsulation devices have 
also shown same interesting results for large animal also even if still not consistent [76]. Baxter 
Healthcare is the author of one of the first prototype of macroencapsulation device. Two sealed 
membranes constituted the designed structure, with an autonomous inlet gate. The outside 
was defined in order to have a gradient membrane to immune-isolate the transplanted cells 
but also to allow the vascular growth. Small animal experiments displayed a significantly high 
level of device vascularization in the subcutaneous site 1 year after the implant. This promising 
approach could be considered the first generation of the actually known TheraCyte Device.
3.4. Organ extracellular matrix-derived scaffold
Extracellular matrix (ECM) can be defined as a heterogeneous, connective network composed 
of several fibrous glycoproteins able to coordinate cellular functions providing a physical 
architecture, mechanical stability and biochemical cues necessary for tissue morphogenesis 
and homeostasis [77]. These qualities will make ECM a potential successful strategy in order 
to obtain a bioactive scaffold supporting in-vivo cellular viability. Recently decellularization 
protocols have been implemented in order to achieve an ECM-based scaffold that recapitulate 
the tridimensional architecture of the organ from which, cell intended to be seeded, had been 
harvested, as well as its biological-specific features [78]. The importance of using an organ-
specific ECM relies on the opportunity of working with a natural, biocompatible, bioactive 
and structural scaffold. Specific properties of extracellular matrix and its application in the 
diabetes treatment will be discussed below.
4. Extracellular matrix as a template for cell culturing
The extracellular matrix ECM is an organ-specific complex system composed by a plethora 
of molecules (structural and non-structural) created by the tissue-/organ-specific cells, and 
deposited into the nearby medium to provide biophysical and biochemical support to the 
surrounding cells. Originally identified as an inert and passive structural architecture, today 
its role has been completely transformed and the entire scientific community indicates ECM 
as an active environment able to support viability, growth and differentiations both stem [79] 
and differentiated cells. In particular it has been reported how ECM plays a crucial position, 
being essential part of micro environmental stem cell niches [80] and being a substantial part 
of any given tissue. ECM is composed of a multitude of supporting bioactive molecules that 
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are secreted, in different quantities and composition by resident cells in order to support 
 tissue-/organ-specific cellular function(s) specific of each tissue or organ.
The most important constituents of ECM are represented by macromolecules: polypeptide 
chain of collagen, laminin, fibronectin and glycosaminoglycans. It is important to highlight 
how this composition could change not only during physiological aging but also under path-
ological conditions that are able to really upset the whole ECM structure (e.g. liver fibrosis). 
In native pancreas, ECM lives a sort of “environmental dynamic reciprocity” with pancreatic 
cells (belonging both to exocrine and the endocrine part).
Islets isolation is a process where Langerhans islets are detached from ECM by the progres-
sive enzyme-based ECM degradation [81]. In other words, the entire cellular compartment is 
stripped of its surrounding environment leading, in case of islets transplantation, to a very 
low survival rate around 10% of grafted islets [82]. Obviously the low graft success is not just 
the consequence of ECM absence being also related to the transplant site characteristics and to 
a hypoxic state in short- and long-term period, as well as to immunological rejection. Matrix 
composition is particular important for islets homeostasis and stability.
Pancreatic ECM is an intricate tridimensional network enriched by multiple carbohydrate 
and protein which, through a system protein-integrin orchestras islets stability, growth, dif-
ferentiation and death. In this regards, the presence of a specific structure, known as “base-
ment membrane”, is essential. This cytological structure, strictly attached to cells is the final 
activator of specific pathways via interactions between ECM proteins and dedicated integ-
rins. With all these intrinsic properties it is easy to understand how ECM could represent 
the “ideal” scaffold recapitulating most of the qualities needed such as presence of bioactive 
molecules, mechanical strength and tridimensional environment.
Moreover these potentials have the additional advantages to be organ specific.
With these bases, the use of an extracellular matrix scaffold as a template for cell seeding can 
be perfectly in line with the paradigm of tissue engineering.
4.1. Decellularization technology
Decellularization is defined as a multi-step process able to separate the organ/tissue extracel-
lular matrix from its inhabitant cellular component, leaving ECM relatively intact with regard 
to tridimensional characteristics and biological properties. Resultant structure is an acellular 
scaffold, which recapitulates the native tissue/organ features furnishing an ideal template to 
be seeded with new cell families. In 2011 Crapo et al. has profoundly examined all the tech-
niques that can be applied to remove cells from the surrounding ECM [83].
They have divided decellularization techniques in three major types that are still valid today:
1. Chemical decellularization
2. Biological decellularization
3. Physical decellularization
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4.1.1. Chemical decellularization
Chemical decellularization is based on the use of chemical agents in order to detach the cells 
from ECM, catalyzing hydrolytic biomolecular degradation.
Usually, these substances can be acids or bases.
Most common acids used for this purpose are acetic and paracetic acids that have demon-
strated good capacity for cellular removal but they also seemed to be too aggressive to ECM 
structure with an excessive loss of ECM mechanical properties [84]. Calcium hydroxide, 
sodium sulfide and sodium hydroxide are the most common bases utilized as decellulariza-
tion agents. It is generally accepted that their use, during decellularization, leads to the elimi-
nation of growth factors that enrich the ECM resulting in a loss of bioactivity [85]. For above 
described reasons, acids and bases are not yet universally used.
Detergents (ionic, nonionic and zwitterionic) may represent the most important chemical 
agents used for decellularization. Solubilizing cell membranes (cytoplasmatic and nuclear) 
[86] and separating DNA from proteins, they are therefore effective in removing cellular 
material from the tissue or the organ treated [77].
Sodium dodecyl sulfate (SDS) and Triton X-100 are the most common used detergents present 
in decellularization protocols [87].
SDS is an ionic, synthetic, organic compound with an established experience in tissue engi-
neering of decellularized tissues. Dedicated scientific literature offers many protocol based on 
the use of SDS for organ or tissue decellularization [88–90].
Triton X-100 (TNX-100) is a nonionic surfactant composed by a hydrophilic polyethyl-
ene oxide chain and an aromatic hydrocarbon lipophilic or hydrophobic group [91]. By its 
chemical properties, Triton X-100 can effectively remove cells from tissue but seems to be less 
aggressive compared to SDS (even bringing to an ECM degradation) and so more useful for 
thicker tissue [92]. Furthermore, several reports [93, 94] demonstrated how SDS is more effec-
tive in removal nuclear material (and consequently, shortening the risk related to residual 
presence of immunological material).
Finally zwitterionic detergents including 3-[(3-cholamidopropyl) dimethylammonio]-1-prop-
panesulfonate (CHAPS), sulfobetaine-10 (SB-10) and SB-16 have shown encouraging results, 
with an important preservation of ECM biological cues but final results need to be more 
studied [95].
4.1.2. Biological decellularization
Biological decellularization involves the use of biologic enzymatic and non-enzymatic agents 
able to specifically remove of cell residues or undesirable ECM constituents. Enzyme such 
nucleases (DNases or RNases) are the perfect archetype centered on their capacity to cleave 
nucleic acid sequences aiding, in such this way, to eliminate nucleotides after cell lysis [96]. 
Non-enzymatic agents are mainly represented by chelating agents, such as ethylenediami-
netetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). Through metal ions, 
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segregating EDTA and EGTA can separate cells from ECM. Unfortunately these agents are 
not particularly effective if used alone. For this, most of the time, they are added in a multi-
step protocol [97–99].
4.1.3. Physical decellularization
Physical decellularization protocols include several procedures that exploit physical strate-
gies in order to remove cell from ECM, counting temperature-protocols (freeze-thaw cycles), 
mechanical-protocols (via the agitation and the immersion of samples) and pressure-based 
protocols [100]. Temperature-based decellularization protocols are relatively simple proce-
dures that only necessitate of multiple freeze-thaw cycles to be effective in cellular removal 
[101]. If, on one hand, these protocols seem to be satisfying for cellular removal, on the other 
one, multiple temperature changes cause important damages on final tridimensional ECM 
ultrastructure [102]. Freeze-thaw cycles technology is especially appealing for the decellular-
ization of simple structure such as tendon or cartilage-base organs but results hardly appli-
cable on more structural complex architectures (pancreas, kidney or liver). Samples shaking 
and immersion have instead a strategic role and they are often used for tissue engineering. 
Most of the times these protocols are used when samples to decellularized are small and 
without dedicated vascular inlet of outlet such as pre-cut parenchyma cubes of tissue, blood 
vessels [103] or bone fragments [104]. These techniques provide numerous benefits, such as 
the possibility to simply change the duration of protocol (and therefore the time-of-contact 
between detergent and sample) or the shaking force. The choice of the liquid immersion, the 
total duration time or the shaking force (expressed by rpm in case of orbicular shaking) per-
mit a variety of different protocols targeted on the density of native tissue.
However, the achievement of an homogeneous decellularization state remains one of the 
main limit of immersion and shacking techniques, also considering that sample external sur-
faces will be more treated (with a major probability of ECM degradation) compared to the 
inner parts (that could contain cellular residuals at the end of the process).
4.2. Pancreas-specific ECM
Pancreas ECM results composed by proteins belonging to the basement membrane (collagen, 
laminin, fibronectin, nidogen/entactin, vitronectin and perlecan) and by proteoglycans (HS 
proteoglycan, syndecan, glypican, betaglycan and chondroitin sulfate proteoglycans).
4.2.1. Basement membrane ECM components
Collagen fibers are responsible both for structural strength of pancreatic ECM as well as for 
biological action including cellular adhesion and morphogenesis: collagen I, II, III, IV V and 
VI are specifically represented in the islets ECM [104, 105]. Their functions are still not com-
pletely clear moreover if considering their role on the pancreatic endocrine pathways. As 
acutely reviewed by Poole-Warren et al. [106], Collagen I molecules seem to promote islets 
survival [107] but decreasing at the same time insulin release. Furthermore collagen prop-
erties can be exploited only with the presence of specific proteins of surface: the integrins 
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(Int) [108, 109]. These small particles, classified as Int-α1β1, Int-α2β1, Int-α10β1 and Int-α11β1 
have been shown to act as receptor supporting matrix-cellular interactions via the subunit α 
of collagen 1 fibers [110].
Beyond the collagen, laminin proteins are plenty involved in the structural ECM pancre-
atic architecture. Laminin takes part in the structural integrity of the extracellular matrix by 
bounding to collagen, nidogen and glycosaminoglycan fibers [111]. Laminin proteins have 
been localized in the islets cells permeating their islet’s microvasculature, but their actions are 
still under debate. Laminin-islets relationship is controlled by the presence of following inte-
grins: Int-α1β1, Int-α2β1, Int-α3β1, Int-α6β1, Int-α7β1, Int-α9β1, Int-αvβ3, Int-αvβ5, Int-αvβ8 
and Int-α6β4 with islets morphogenesis functions (α3 and β1) [112] and pancreas develop-
ment (α6) [113]. Finally, vitronectin is an ECM protein expressed during human fetal islets 
development. Its correct pathway is essential for the appropriate growth of islets to “mature” 
β cells and moreover for their migration acting as mobility promoter [114].
4.2.2. Proteoglycans ECM components
Proteoglycans are heavily glycosylated proteins that take ubiquitously part in most of all organs 
and tissues both with a structural and deposit activity. Their composition is based on a core 
protein with several different, negatively charged, protein chains (GAGs) attached. Different 
protein chains bring to different proteoglycans [115]. Negative charge is crucial for the deposit 
role of this protein being able to conserve specific growth factors, cytokines and chemokines 
(that differ from tissue to tissue in terms of composition) releasing them just if necessary [116].
4.3. Whole organ decellularization and regenerative medicine
Whole organ perfusion is the most commonly used technology, if the target sample is an 
entire organ. This technique exploits the organ native vascular system to homogenously 
perfuse the organ with selected detergent(s) [117]. Perfusion-decellularization is the most 
consistent method to obtain decellularized whole organ scaffolds due to the native vascular 
architecture, which is naturally designed to permit the delivery of oxygen and nutrients by 
blood flux. This allows the same time-to-contact between detergent(s) and cells in the entire 
organ by an anterograde or a retrograde perfusion. Likewise, the presence of a vascular outlet 
(most of the times represented by the native venous outflow system) allows an efficient strat-
egy to eliminate cellular debris deriving from decellularization. Whole organ perfusion has 
been already established for several organs or tissues that differ in terms of size, origin (small 
or large animal model and human) and physiopathological conditions [118]. Obviously, as 
described for immersion/shaking technology, the appropriateness of the perfusion protocol 
must be pointed on the organ properties (moreover size and resident cell density).
This technology has been also applied in the attempt of creating a bioengineered pancreas.
Basically the idea is to customize clinical-relevant size acellular pancreas that can be secondly 
repopulated with patient-own endocrine cellular population and then transplanted in the same 
patient. If successful, this approach could address the limitations that today affect diabetes 
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treatment. It could be created a non-immunological recellularized scaffold with functional 
islets, β cells or human-induced pluripotent stem cells (hiPSC) derived to β cells and endothe-
lial cells subsequently orthotopically transplanted in the patient whose cells were harvested. In 
this scenario, animal source could provide a hypothetical unlimited pool of scaffold to repopu-
late and stem cells (mesenchymal or iPS) can be used for the repopulation.
A bioengineered approach could so provide an unlimited source of transplantable pancreas, 
eliminating the organ shortage, and, at the same time, the use of patient-own cells could avoid 
(or limit) the use of immunosuppressive drug regimes.
The entire decellularization development must be balanced according to the final desired 
quality of the extracellular matrix. This quality is currently evaluated by histological staining, 
DNA content, collagens and proteoglycans assessment and tridimensional imaging technolo-
gies (scanning electron microscopy). This assessment provides crucial data not only on the 
effective cellular removal but also about the biological and structural properties of the decel-
lularized matrix intended to seed.
If decellularization technology has provided satisfying results in term of pancreas decellu-
larization and ECM maintenance, recellularization strategies seems to be the most important 
hurdle, still not yet overcome.
These, together with engineering significant advances for the manufacturing of dedicated 
bioreactors, are the next steps to go.
4.4. Recellularization technology
Recellularization strategies play a key role for the creation of a functional bioengineered 
organoid. Working recellularization requires a proper cell source (considering both mature or 
stem cell origin), an optimal seeding method and a long-term culture system (available with 
appropriate bioreactors). Scaffold recellularization needs tree different cell group, belong-
ing to parenchymal, vascular and supporting types respectively with different tasks and 
responsibilities.
Parenchymal cells are responsible for the effective organ function whereas vascular cells must 
entirely cover the vascular extracellular matrix providing a suitable blood flux (after trans-
plantation) both as inlet (with oxygen and nutrients delivering) as well as in outlet for meta-
bolic wastes spill.
In this regards, vascular coverage during recellularization is essential for the success, and 
it must be achieved covering as much ECM as possible. Missing ECM parts, which are not 
protected by vascular cells, will directly expose ECM to the blood flow, resulting in an almost 
instant activation of the coagulative cascade and in the formation of blood clots. This situation 
will bring to a subsequently blood stoppage directed to the entire portion downstream the 
clot, with final seeded cells death [119].
Finally supporting cells must provide an active sustain for parenchymal and vascular cellular 
families.
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Pancreas scaffold recellularization can be performed via vascular perfusion (using the same 
principle utilized to remove cells). Inlet pancreatic vasculature can be mainly accessed by 
splenic and pancreaticoduodenal artery.
Pancreatic inlet can also exploit the presence of the pancreatic duct via a retrograde flow. 
Pancreatic outlet vasculature relies on the portal and the splenic vein.
4.5. Cell-on-scaffold technology toward bioartificial pancreas: state-of-art
Cell-on-scaffold technique has been already examined in order to produce a pancreatic 
organoid.
One of the first pioneeristic studies that explored the possibility of using ECM matrix as a tem-
plate for islets seeding has been proposed by De Carlo et al. in 2010. In their report 240-μm slices 
of rat pancreatic and hepatic acellular were decellularized by a detergent-based protocol (4% 
sodium deoxicholate was used) and then seeded with islets after static culture conditions (37°C, 
95% O2 and 5% CO2 in RPMI-1640 medium added with 5.6 mM glucose, 100 IU/ml of penicillin and 100 μg/ml of streptomycin). Furthermore pancreatic islets (N = 50) were seeded on five acel-
lular matrix and cultured under standard conditions. After 7 days, the islet-matrix complexes 
were inserted into synthetic, tubular PVA/PEG devices and prepared for in-vivo implant. Rats 
were then made diabetic and PVA/PEG devices (containing islets and matrix) were implanted. 
Results have demonstrated, in an in-vivo follow-up up to 6 weeks, how pancreatic devices 
reacted to glucose acute stimula with insulin delivery and a decreasing dose of daily insulin 
needed to maintain the euglycaemic condition [120]. To our knowledge, in the same year, Ott’s 
lab proposed for the first time a rat pancreatic whole pancreas scaffold (obtained via deter-
gent perfusion) afterwards seeded with human islets and supporting human MSCs. Results 
were very fascinating showing effective tridimensional growth of cells on the matrix with good 
response to glucose stimula [121]. Both these studies have shown important starting lines for 
the use of this technology to produce a functional bioengineered pancreas. However they have 
also highlighted significant limitations, some of which have been already overtaken.
Herein we describe the most important findings regarding the use of a whole organ pancre-
atic scaffold from different models with the aim to manufacture a transplantable bioengi-
neered pancreas.
4.5.1. Small animal models
Small animal model represent the baseline for basic science in terms of costs and prospective 
translational results. For this reason small animal model has been the first to be investigated.
One of the first complete proof-of-concepts of a murine whole organ pancreas decellulariza-
tion has been offered by Goh et al. in 2013 [122]. After a midline laparotomy the pancreas was 
carefully harvested preserving intact vascular inlets that have been then cannulated and used 
as inlets for retrograde perfusion with a flow of 8 ml/min. A multistep protocol with 0.5% SDS 
and 1% Triton X-100 has been chosen. Cells for repopulation (AR42J acinar cell line for the 
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exocrine component and MIN-6 β cell for the endocrine one) were cultured in standard static 
condition and then seeded on the acellular scaffold. AR42J cells were injected through the 
main pancreatic duct (30 × 106) cells whereas MIN-6 β cells (30 × 106) via the hepatic vein. The 
seeded pancreas was cultured under static conditions at 37°C with a 95% air/5% CO2 atmo-sphere for 5 days and then implanted by a dorsal subcutaneous pocket of an adult mouse 
for biocompatible preliminary tests. Results have demonstrated an optimal feasibility about 
decellularization with preservation of ECM composition. Secondly recellularization was eval-
uated in terms of cellular engraftment, survival and functionality by Immunohistochemistry 
(IHC). Reconstructed pancreas showed a homogenous distribution of cell types with a mini-
mal apoptosis rate (detected by TUNEL staining) less than 18% and robust cellular function-
ality expressed by C-peptide staining positivity and finally confirmed by up-regulation of 
insulin genes. After 14 days, subcutaneous implantation pancreatic organoid was harvested 
and established as biocompatible organoid able to positive regulate a neoangiogenetic action. 
This paper has set the bases for all the subsequent experiments.
Recently a group headed by Struecker has refined the entire process providing, for the first 
time, a proof-of-concept for the repopulation of the decellularized rat pancreas with func-
tional islets of Langerhans [123]. Briefly rat pancreas was decellularized via vascular perfu-
sion (1% Triton X: 0.5% SDS and 1% Triton X-100) with a flow-rate around 10 ml/min and then 
repopulated with approximately 2000 islets via the pancreatic duct to test viability and func-
tionality of the islets after the process. Ex-vivo TUNEL staining and glucose-stimulated insulin 
secretion (GSIS) revealed how islets were viable and functional after the injection inside the 
acellular scaffold.
Both the presented studies have analyzed the opportunity to use mature and already differ-
entiated cells to repopulate pancreas whole organ scaffold.
A further progress toward the creation of an ECM-pancreas can be accomplished exploiting 
the use of stem cells driven in their growth and specific differentiation by precise ECM bio-
logical cues. Thus stem cells can be considered a potent and encouraging cell source for tissue 
engineering [124]. Accordingly to this concept, Wan et al. has just proposed a study about the 
possibility to culturing iPSCs derived pancreatic β cells on decellularized ECM [125]. After 
peristaltic artery perfusion with detergents, decellularized ECM-based pancreas were seeded 
with already differentiated into β cells like iPSCs (approx. 3 × 106) by two different methods 
(vascular perfusion and multipositional parenchymal injection). In-vitro continuous monitor-
ing exhibits maintained insulin, C-peptide and glucagon expression. Additionally, insulin 
level expression in the perfusated media was twofold higher than those levels obtained by 
traditional bidimensional culturing.
4.5.2. Large animal models
Even if encouraging results have been reported for small animal model, it is mandatory to aim 
to a functional bioengineered pancreas with clinically relevant size.
That way the use of a large animal model has been investigated.
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The main difficulty in the switching from small to large animal is mainly due to the higher 
stiffness of the pancreatic parenchyma and to the larger volume that has to be decellularized. 
In this regards, decellularized protocols could not be too aggressive in order to preserve ECM 
native characteristics. In 2013, research group headed by Orlando published the proof-of-
concept for the achievement of a porcine decellularized whole organ scaffold [126]. Vascular-
based retrograde peristaltic perfusion via superior mesenteric vein and pancreatic duct with 
nonionic detergent (1% Triton X-100) guarantied pancreatic cellular removal. Pancreatic extra-
cellular matrix biocompatibility was tested by the static short-term (7 days) cellular seeding 
with human amniotic fluid stem cells. This type of cells has been also proposed as a potential 
source of insulin-secreting cells [127]. To validate the hypothetical capacity of acellular ECM-
based pancreas like scaffold to sustain endocrine pancreatic function, porcine pancreas scaf-
fold was repopulated with porcine islets and insulin secretion was ex-vivo measured under 
different glucose stimula and at several time points. Results proposed showed a significant 
similarity to physiological circumstances with higher insulin release in response to higher 
glucose concentration. Katsuki et al. have also proposed analogous results in 2016 [128] with 
the creation of a portioned repopulated porcine pancreas.
4.5.3. Discarded human pancreas as a source of ECM
The use of discarded human organs has been explored as a possible source of organ to 
decellularize. This opportunity is based on the incredible amount of organ that, annually 
in the USA, are retrieved for transplantation purposes but finally discarded for various rea-
sons. Orlando et al. described this scenario envisioning [129], in a future not so distant, that 
a discarded organ will be use to build an acellular human scaffold subsequently repopu-
lated by patients own cells. The final result will be a bioengineered pancreas composed by 
human-derived extracellular matrix as well as recellularization cell type. The hypothesis 
to recycle discarded human organs for organ bioengineering projects, hinges on the theory 
that decellularized human ECM could be the perfect environment for human cells during 
recellularization.
In 2015, our group has explored the use of discarded pancreas as a source from which 
obtain acellular whole organ scaffolds [130]. Compared to data achieved on the porcine 
model, an additional inlet access was demonstrated crucial switching from a two-way 
perfusion (pancreatic duct and superior mesenteric vein) to a three-way perfusion system 
(pancreatic duct, superior mesenteric artery and splenic artery). This adjustment brought to 
a more homogenous distribution of the detergent used (1% Triton X-100) permitting a rela-
tive more gentle approach (Triton X-100 is considered less aggressive than SDS). Staining 
and DNA content confirmed the cellular removal as well as the preservation of the most 
important pancreatic ECM elements and growth factor that enriched the human native pan-
creatic parenchyma. Besides important results about static seeding with human islets and 
dynamic peristaltic seeding with human primary pancreatic endothelial cells, crucial infor-
mation has been obtained by the analysis of ECM immune properties. In fact, to the best of 
our knowledge, it is the first time that human pancreas ECM documents an immunosup-
pressive T-reg promoting properties paving the way for its possible use as immunosup-
pressant (Table 1).
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Table 1. Timeline of the major advances in insulin treatment, islets and pancreas transplantation and pancreas 
bioengineering.
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5. Conclusion and future perspectives
In the last decade, regenerative medicine and organ bioengineering have accomplished 
important progress toward the manufacturing of a functional, bioengineered pancreas, 
exploring different options both in terms of platform for decellularization as well as for cell 
type repopulation source. As of now, the emergent use of stem cells appears as an exciting 
and encouraging field to discover. Several crucial hurdles are not yet overcome and require 
important advancements, above all in-vivo short- and long-term functional testing. Despite 
these obstacles, cell-on-scaffold technology holds a huge potential in order to solve the prob-
lem of pancreas shortage creating a solid transplantable alternative.
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